Merck, Moderna skin cancer vaccine reduces disease’s recurrence, spread in large trial
Merck Moderna vaccine
Covered by 4 sources
- NYT Health·1h agoModerna, Merck Say mRNA Vaccine Prevents Melanoma From Returning
Moderna and Merck say the experimental vaccine prevented the return and spread of the cancer in high-risk melanoma patients.
Read at NYT Health → - CBC Health·1h agoMerck and Moderna say mRNA melanoma vaccine hits goals in late-stage trial
Merck and Moderna report that a personalized mRNA vaccine helped prevent skin cancer from returning in high-risk patients. Observers greeted the news with enthusiasm but noted that full data from the ongoing late-stage study has yet to be released.
Read at CBC Health → - Economic Times·2h agoModerna shares soar 135% in a day after cancer vaccine succeeds in late-stage trial
Moderna shares surged after its personalized mRNA cancer vaccine trial showed positive results. The treatment, combined with Keytruda, reduced melanoma recurrence and spread significantly. This marks the first successful late-stage trial for an mRNA cancer vaccine. The findings…
Read at Economic Times → - Globe and Mail Biz·5h agoMerck, Moderna skin cancer vaccine reduces disease’s recurrence, spread in large trial
Moderna shares soared on news of the interim results of the treatment, which combines a made-to-order mRNA vaccine with Merck’s Keytruda
Read at Globe and Mail Biz →